Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Anaplastic Thyroid Cancer-Pipeline Review, H1 2015

Anaplastic Thyroid Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Anaplastic Thyroid Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anaplastic Thyroid Cancer-Pipeline Review, H1 2015', provides an overview of the Anaplastic Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anaplastic Thyroid Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Anaplastic Thyroid Cancer-Overview 8

Pipeline Products for Anaplastic Thyroid Cancer-Comparative Analysis 9

Anaplastic Thyroid Cancer-Therapeutics under Development by Companies 10

Anaplastic Thyroid Cancer-Therapeutics under Investigation by Universities/Institutes 11

Anaplastic Thyroid Cancer-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Anaplastic Thyroid Cancer-Products under Development by Companies 14

Anaplastic Thyroid Cancer-Products under Investigation by Universities/Institutes 15

Anaplastic Thyroid Cancer-Companies Involved in Therapeutics Development 16

Daiichi Sankyo Company, Limited 16

Exelixis, Inc. 17

Genelux Corporation 18

GlaxoSmithKline plc 19

Immune Pharmaceuticals, Ltd. 20

Novartis AG 21

OXiGENE, Inc. 22

Plexxikon Inc. 23

Takeda Oncology 24

Anaplastic Thyroid Cancer-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

cabozantinib s-malate-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ceritinib-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

CLM-3-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CLM-94-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

crolibulin-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

efatutazone-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

fosbretabulin tromethamine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

GLONC-2-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

MLN-0128-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

PLX-8394-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Anaplastic Thyroid Cancer-Recent Pipeline Updates 56

Anaplastic Thyroid Cancer-Dormant Projects 79

Anaplastic Thyroid Cancer-Product Development Milestones 80

Featured News & Press Releases 80

Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 82

Disclaimer 82

List of Tables

Number of Products under Development for Anaplastic Thyroid Cancer, H1 2015 8

Number of Products under Development for Anaplastic Thyroid Cancer-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Anaplastic Thyroid Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 16

Anaplastic Thyroid Cancer-Pipeline by Exelixis, Inc., H1 2015 17

Anaplastic Thyroid Cancer-Pipeline by Genelux Corporation, H1 2015 18

Anaplastic Thyroid Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 19

Anaplastic Thyroid Cancer-Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 20

Anaplastic Thyroid Cancer-Pipeline by Novartis AG, H1 2015 21

Anaplastic Thyroid Cancer-Pipeline by OXiGENE, Inc., H1 2015 22

Anaplastic Thyroid Cancer-Pipeline by Plexxikon Inc., H1 2015 23

Anaplastic Thyroid Cancer-Pipeline by Takeda Oncology, H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Assessment by Combination Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Anaplastic Thyroid Cancer Therapeutics-Recent Pipeline Updates, H1 2015 56

Anaplastic Thyroid Cancer-Dormant Projects, H1 2015 79

List of Figures

Number of Products under Development for Anaplastic Thyroid Cancer, H1 2015 8

Number of Products under Development for Anaplastic Thyroid Cancer-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Daiichi Sankyo Company, Limited

Exelixis, Inc.

Genelux Corporation

GlaxoSmithKline plc

Immune Pharmaceuticals, Ltd.

Novartis AG

OXiGENE, Inc.

Plexxikon Inc.

Takeda Oncology

Anaplastic Thyroid Cancer Therapeutic Products under Development, Key Players in Anaplastic Thyroid Cancer Therapeutics, Anaplastic Thyroid Cancer Pipeline Overview, Anaplastic Thyroid Cancer Pipeline, Anaplastic Thyroid Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com